Program
Terbinafine
Also written as “MOB015B”, “terbinafine” and “Terbinafine Hydrochloride”.
Its studies are mostly in Onychomycosis · Erythema · Tinea Pedis · Mycoses · Fasting, led by 13 companies.
Drug pageTerbinafine: every studyMany companies study it; this page follows only the 33 they lead. All 46 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Moberg Pharma ABits history only | 71 open or running | phase 3since Aug 4, 2016 | Mar 15, 2013 | none ahead |
| Novartisits history only | 70 open or running | phase 3since Jun 30, 2005 | Nov 2, 1999 | none ahead |
| Almirallits history only | 30 open or running | phase 3since Sep 8, 2015 | Sep 8, 2015 | none ahead |
| Celtic Pharma Development Servicesits history only | 20 open or running | phase 3since Mar 19, 2010 | Mar 18, 2010 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Jan 26, 2011 | Jan 26, 2011 | none ahead |
| Hikma Pharmaceuticalsits history only | 20 open or running | no phasesince Jan 15, 2008 | Jan 15, 2008 | none ahead |
| Nitric BioTherapeuticsits history only | 20 open or running | phase 2since Mar 1, 2010 | Mar 1, 2010 | none ahead |
| Teva Pharmaceutical Industriesits history only | 20 open or running | phase 1since Jan 30, 2009 | Jan 30, 2009 | none ahead |
| Viatrisits history only | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| GlaxoSmithKlineits history only | 10 open or running | phase 1since Jan 17, 2013 | Jan 17, 2013 | none ahead |
| NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)its history only | 10 open or running | phase 1since Jun 3, 2008 | Jun 3, 2008 | none ahead |
| Onyx Axiomits history only | 11 open or running | phase 2since Nov 20, 2025 | Nov 20, 2025 | Jan 2028phase 2 · NCT07382427 |
| United Laboratoriesits history only | 10 open or running | phase 2since Jun 24, 2019 | Jun 24, 2019 | none ahead |
Also a collaborator on its studies: PPD DEVELOPMENT, LP.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 14 studies since Nov 2, 1999.
- Mar 18, 2010Celtic Pharma Development Services’ first study: phase 2 study in OnychomycosisNew to Celtic Pharma Development ServicesCeltic Pharma Development Services · NCT01790165 · 27 enrolled
- Mar 19, 2010Phase 3 study in OnychomycosisCeltic Pharma Development Services · NCT01145807 · 738 enrolled · United States
- Jan 26, 2011Dr. Reddy's Laboratories’ first studies: 2 phase 1 studiesNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01286701, NCT01286688
- Sep 8, 2011Phase 3 study in Tinea PedisNovartis · NCT01433107 · 290 enrolled · China
- Nov 28, 2011Phase 2 study in OnychomycosisNitric BioTherapeutics · NCT01484145 · 25 enrolled · United States
- Jan 17, 2013GlaxoSmithKline’s first study: phase 1 study in MycosesNew to GlaxoSmithKlineGlaxoSmithKline · NCT01772212 · 30 enrolled
- Mar 15, 2013Moberg Pharma AB’s first study: phase 2 study in Distal Subungual OnychomycosisNew to Moberg Pharma ABMoberg Pharma AB · NCT01814020 · Sweden
- Sep 8, 2015Almirall’s first studies: 2 phase 3 studies in OnychomycosisNew to AlmirallAlmirall · NCT02549001, NCT02547701
- Aug 4, 20162 phase 3 studies in Distal Subungual OnychomycosisMoberg Pharma AB · NCT02859519, NCT02866032
- Mar 21, 2017Phase 3 study in Onychomycosis of ToenailAlmirall · NCT03094468 · United States, Canada
- Aug 1, 20173 phase 1 studiesMoberg Pharma AB · NCT06369727, NCT06369675, NCT03244280
- Jun 24, 2019United Laboratories’ first study: phase 2 study in Tinea PedisNew to United LaboratoriesUnited Laboratories · NCT03999437 · 42 enrolled · Philippines
- Mar 4, 2022Phase 3 study in OnychomycosisMoberg Pharma AB · NCT05279846 · 350 enrolled · United States, Canada
- Nov 20, 2025Onyx Axiom’s first study: phase 2 study in Onychomycosis of ToenailNew to Onyx AxiomOnyx Axiom · NCT07382427 · 200 planned
Ahead
- Jan 2028Primary completion: phase 2 study in Onychomycosis of ToenailOnyx Axiom · NCT07382427
TargetBeta
“Squalene monooxygenase inhibitor; Squalene monooxygenase inhibitor”ChEMBL 37, by rule
“Terbinafine is a long-licensed, generic antifungal drug that inhibits squalene epoxidase (SQLE), an enzyme that may play a role in prostate cancer progression.”study text, by rule · the study
Studies
All 33 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07382427Onychomycosis of Toenail | 2 | Not yet recruiting | Onyx Axiom | Jan 2028 | 200 |
| NCT05279846Onychomycosis · United States, Canada | 3 | Active, not recruiting | Moberg Pharma AB | Jan 2025 | 350 |
| NCT03999437Tinea Pedis · Philippines | 2 | UNKNOWN | United Laboratories | Dec 13, 2019 | 42 |
| NCT06369727Erythema · United States | 1 | Completed | Moberg Pharma AB | Feb 15, 2018 | 250 |
| NCT06369675Erythema · United States | 1 | Completed | Moberg Pharma AB | Nov 14, 2017 | 45 |
| NCT03244280Onychomycosis · United States | 1 | Completed | Moberg Pharma AB | Apr 23, 2018 | 20 |
| NCT03094468Onychomycosis of Toenail · United States, Canada | 3 | Withdrawn | Almirall | Oct 2019 | 0 |
| NCT02866032Distal Subungual Onychomycosis · Germany, Poland, United Kingdom | 3 | Completed | Moberg Pharma AB | Jun 10, 2020 | 452 |
| NCT02859519Distal Subungual Onychomycosis · United States, Canada | 3 | Completed | Moberg Pharma AB | Nov 13, 2019 | 365 |
| NCT02549001Onychomycosis · Belgium, Bulgaria, Czechia and more | 3 | Completed | Almirall | Sep 17, 2018 | 953 |
| NCT02547701Onychomycosis · Belgium, Germany, Italy and more | 3 | Completed | Almirall | Sep 2017 | 20 |
| NCT01814020Distal Subungual Onychomycosis · Sweden | 2 | Completed | Moberg Pharma AB | Jul 2014 | |
| NCT01772212Mycoses | 1 | Completed | GlaxoSmithKline | Mar 15, 2011 | 30 |
| NCT01484145Onychomycosis · United States | 2 | Completed | Nitric BioTherapeutics | Mar 2012 | 25 |
| NCT01433107Tinea Pedis · China | 3 | Completed | Novartis | Feb 2012 | 290 |
| NCT01286701Lecithin Cholesterol Acyltransferase Deficiency · Canada | 1 | Completed | Dr. Reddy's Laboratories | Feb 2002 | 18 |
| NCT01286688Fasting · Canada | 1 | Completed | Dr. Reddy's Laboratories | Feb 2002 | 36 |
| NCT01145807Onychomycosis · United States | 3 | UNKNOWN | Celtic Pharma Development Services | Feb 2012 | 738 |
| NCT01790165Onychomycosis | 2 | Completed | Celtic Pharma Development Services | Jan 2010 | 27 |
| NCT01080079Onychomycosis · United States, Canada | 2 | Completed | Nitric BioTherapeutics | Nov 2011 | 168 |
| NCT00833664Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jan 2002 | 22 |
| NCT00833586Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jan 2002 | 28 |
| NCT00691184Onychomycosis · United States | 1 | Completed | NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) | Jun 2005 | 56 |
| NCT00648713Healthy · United States | 1 | Completed | Viatris | Mar 2004 | 36 |
| NCT00647647Healthy · United States | 1 | Completed | Viatris | Mar 2004 | 36 |
| NCT00602342Onychomycosis · United States | – | Completed | Hikma Pharmaceuticals | Apr 2004 | 30 |
| NCT00602251Onychomycosis · United States | – | Completed | Hikma Pharmaceuticals | Apr 2004 | 30 |
| NCT00459537Onychomycosis · Finland, France, Germany and more | 3 | Completed | Novartis | Jan 2009 | 1,029 |
| NCT00443898Onychomycosis · United States, Canada, Iceland | 3 | Completed | Novartis | Jun 2008 | 518 |
| NCT00443820Onychomycosis · United States, France, Germany | 3 | Completed | Novartis | Jun 2008 | 526 |
| NCT00117767Tinea Capitis · United States | 3 | Completed | Novartis | Mar 2006 | 720 |
| NCT00117754Tinea Capitis · United States | 3 | Completed | Novartis | 720 | |
| NCT00002394Candidiasis, Oral · United States | – | Completed | Novartis | 30 |
How it is read
Names in the registry
- “MOB015B”, 7 entries
- “terbinafine”, 4 entries
- “Terbinafine”, 3 entries
- “Terbinafine Hydrochloride”, 3 entries
- “Terbinafine HCl 250mg tablets”, 2 entries
Codes read as this program: P3058.
Conditions, from the studies’ own filings
- Onychomycosis, 19 studies
- Erythema, 2 studies
- Tinea Pedis, 2 studies
- Mycoses, 1 study
- Fasting, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.